|Dr. Scott Koenig M.D., Ph.D.||Pres, CEO & Director||954.14k||N/A||1952|
|Mr. James Karrels||Sr. VP, CFO & Corp. Sec.||577.9k||115.53k||1967|
|Mr. Eric Blasius Risser||Chief Operating Officer||571.98k||N/A||1973|
|Dr. Ezio Bonvini||Sr. VP of Research & Chief Scientific Officer||612.21k||264.03k||1954|
|Dr. Thomas M. Spitznagel Ph.D.||Sr. VP of Technical Operations||550.97k||204.5k||1967|
|Dr. Christopher Shayne James M.D.||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Jeffrey Stuart Peters||Sr. VP & Gen. Counsel||N/A||N/A||1972|
|Dr. Stephen L. Eck M.D., Ph.D.||Sr. VP of Clinical Devel. & Chief Medical Officer||N/A||N/A||1955|
|Ms. Lynn Cilinski||VP, Controller & Treasurer||N/A||N/A||1958|
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
MacroGenics, Inc.’s ISS governance QualityScore as of 1 September 2022 is 7. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 7; Compensation: 6.